Entera’s Oral Osteoporosis Therapy Shows Promising Bone Density Gains in Phase II Trial

Entera Bio’s oral anabolic therapy EB613 achieved statistically significant improvements in bone mineral density (BMD) in postmenopausal women during a Phase II trial (NCT04003467). At the 2025 North American Menopause Society Annual Meeting, results showed that a 2.5mg daily dose increased lumbar spine density by 3.1%, hip by 2.3%, and femoral neck by 2.0% versus placebo after six months. These findings validate the selected dose for Phase III development. EB613, a once-daily oral PTH (1-34) tablet, represents a potential breakthrough as the first oral bone-building therapy for women at high fracture risk. The oral format could improve accessibility and adherence, overcoming limitations of injectable anabolic treatments. Entera noted that similar bone-strength gains were previously observed in women more than a decade post-menopause, reinforcing its therapeutic promise.

28-10-2025